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Objectives: This study aims to assess vaginal bleeding patterns and cycle control of oral contraceptives containing estetrol (E4) combined
with either drospirenone (DRSP) or levonorgestrel (LNG).
Study design: An open-label, multicentre, randomised, dose-finding study lasting six cycles in healthy women aged 18–35 years was used.
Four treatments (15 mg or 20 mg E4, combined with either 3 mg DRSP or 150 mcg LNG) were administered in a 24/4-day regimen. A
marketed dosing regimen of estradiol valerate with dienogest (E2V/DNG) served as reference since it contains (like E4) a natural oestrogen.
Results: A total of 396 women were randomised, of whom 389 received study medication, and 316 completed the study. By cycle 6, the
frequencies of unscheduled bleeding and/or spotting and absence of withdrawal bleeding were the lowest in the 15 mg E4/DRSP group
(33.8% and 3.5%, respectively). In the E2V/DNG reference group, these frequencies were 47.8% and 27.1%, respectively. By cycle 6, the
frequency of women with absence of withdrawal bleeding was b20% for all E4 treatment groups: 3.5–3.8% combined with DRSP and
14.0–18.5% combined with LNG. By cycle 6, unscheduled intracyclic bleeding was reported by b20% of women in the 20 mg E4/LNG
group (18.9%) and in the 15 mg E4/DRSP group (16.9%).
Conclusion: This study showed that, of the four treatment modalities investigated, the 15 mg E4/DRSP combination has the most favourable
bleeding pattern and cycle control.
Implications: Due to its favourable bleeding pattern and cycle control, the 15 mg E4/DRSP combination is the preferred combination for
further phase III clinical development.
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The bleeding pattern of combined oral contraceptives
(COCs) containing ethinyl estradiol (EE) is perceived as
satisfactory by women, which may be due to the effective
stabilisation of the endometrium, induced by its potent
oestrogenic activity. However, EE causes subjective side
effects [1], and it affects the synthesis of various liver
proteins leading to an increased risk of cardiovascular
complications [2–4]. Strategies have been developed to
lower the EE dose or substitute EE with another oestrogennder theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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were associated with poor bleeding patterns, and therefore,
the development was stopped [7]. Combinations of E2 with
nomegestrol acetate (NOMAC/E2) or estradiol valerate with
dienogest (E2V/DNG) were subsequently developed and led
to acceptable cycle control [7–10] but were still suboptimal
since absence of withdrawal bleeding was reported to be
31% and 20%, respectively [7,9].
The development of new oestrogens such as estetrol (E4)
holds promise for the safety and tolerability of future COCs
[2]. E4 is synthesised by the human foetal liver and is present
only during human pregnancy [11]. In contrast to other
oestrogens, E4 is an antagonist of the membrane oestrogen
receptor alpha, it does not bind to the carrier protein
sex-hormone binding globulin SHBG and it does not change
the activity of relevant cytochrome P450 related liver
enzymes [12,13]. The terminal half-life of E4 is 28 h versus
14 h for E2 [14], an important prerequisite for its
development as a once daily oral drug [15].
Preclinical and phase I clinical research suggests that E4
inhibits ovulation and may be a suitable replacement for EE
in COCs [16–18]. In a phase II, dose-finding study, 5 mg, 10
mg or 20 mg E4 in combination with drospirenone (DRSP)
or levonorgestrel (LNG) completely inhibited ovulation and
decreased ovarian activity dose-dependently [19]. These
combinations also had a limited effect on liver function, lipid
metabolism and bone and growth endocrine parameters [20].
The present phase II, randomised, dose-finding study was
conducted with the aim of selecting an E4/progestin combina-
tion for phase III development. The primary objective was to
investigate the effect of two dosages of E4 combinedwith either
DRSP or LNG on vaginal bleeding patterns and cycle control,
using a COC containing E2V/DNG as a reference.2. Methods
2.1. Design and ethical approval
This was an open-label, multicentre, randomised,
dose-finding study in healthy female volunteers of repro-
ductive age. The study was conducted between September
2010 and 2011 in 10 centres in Finland (ClinicalTrials.gov
identifier NCT01221831). Approval was obtained by the
regional independent ethics committee of the Hospital
District of Helsinki and Uusimaa and by the Finnish
Medicines Agency. The study was conducted in accordance
with the ethical principles established by the Declaration of
Helsinki and the International Conference on Harmonisation
— Good Clinical Practise Guidelines. Written informed
consent was obtained from all participants before enrolment.
2.2. Participants
Healthy women, aged 18–35 years with a body mass
index between 18 and 30 kg/m2 and a regular menstrual
cycle (24–35 days), were eligible for inclusion. Women whowere already using hormonal contraceptives (switchers) and
hormonal contraceptive-naïve women (starters) were able to
participate. Switchers changed from a COC, vaginal ring or
transdermal patch. Women were defined as starters when they
had not used a hormonal contraceptive in the 3 months prior to
randomisation. Women who used any hormonal contraceptive
method within 3 months prior to randomisation, but not at
screening (for starters), or women using a depot progestogen
within 6months prior to randomisation were excluded. Untreated
chlamydia infection also led to exclusion. The other exclusion
criteria were in line with the World Health Organisation's
medical eligibility criteria for COC use [21] and included
contraindications for contraceptive steroids (e.g., a history of, or
existing thromboembolic, cardiovascular or cerebrovascular
disorder or hypertension, defined as systolic and diastolic
blood pressure N140 and N90 mmHg, respectively).
2.3. Treatment
There were five treatment groups: (1) 15 mg E4 plus 3 mg
DRSP (15E4/DRSP), (2) 20 mg E4 plus 3 mg DRSP (20E4/
DRSP), (3) 15 mg E4 plus 150 mcg LNG (15E4/LNG), (4)
20 mg E4 plus 150 mcg LNG (20E4/LNG) and (5) E2V plus
DNG (E2V/DNG) (commercial packaging of 4-phasic
Qlaira®, Bayer HealthCare, Germany). E2V/DNG was
chosen as a reference because it is the only global COC
containing a natural oestrogen (E2V), like E4.
To achieve equal distribution across the groups, rando-
misation was stratified by switchers, starters and sites. After
randomisation, switchers completed their last pill blister (or
completed the vaginal ring or patch treatment cycle) before
starting study treatment. Starters took their first study
medication on the first day of the first menstruation
occurring after randomisation. Participants completed six
treatment cycles of 28 days. For the E4 groups, one cycle
comprised of 24-study medication days, followed by 4
placebo days. Women assigned to E2V/DNG took active
study treatment for 26 days followed by 2 placebo days,
according to the labelling of Qlaira®.
2.4. Assessments
Study visits were scheduled at randomisation, on days
1–14 of treatment cycles 2, 3, 4 and 5 and between days 25
and 28 of cycle 6 (final study visit). Women completed a
daily diary to monitor vaginal bleeding. The intensity of
vaginal bleeding was evaluated based on the number of
sanitary protections needed (0, 1 or ≥2).
Safety was evaluated by recording treatment-emergent
adverse events (TE-AEs), standard laboratory safety results,
physical and gynaecological examination and vital signs.
Of drug-related TE-AEs, headache/migraine and anxiety/
depression were considered of special interest.
A pregnancy test (urinary β-hCG) was performed at
randomisation and at monthly visits. Ovulation inhibition
was assessed during cycles 1–4 by urinary pregnanediol
glucuronide measurements [22].
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The primary aim of the study was to assess vaginal
bleeding patterns and cycle control of 15 and 20 mg E4
combined with either DRSP or LNG, administered during
six treatment cycles in a 24/4-day regimen.
The purpose of the study was to find a dosing
combination with not more than 20% absence of withdrawal
bleeding and not more than 20% unscheduled intracyclic
bleeding in cycle 6. The optimal E4/progestin combination
will be selected for further phase III clinical development.
Cycle control was evaluated on the basis of daily vaginal
bleeding patterns. The primary bleeding parameters were
unscheduled bleeding and spotting combined (referred to as
bleeding/spotting) and absence of withdrawal bleeding. Sec-
ondary bleeding parameters comprised a bleeding/spotting cycle
pattern by cycle day and early withdrawal bleeding (i.e.,
occurring between days 21 and 24). Bleeding or spotting
reported during cycle days 5–24was considered unscheduled. If
bleeding or spotting did not occur on cycle days 1 and 2, but
occurred on cycle day 3 or 4, it was also considered unscheduled
(except for days 1–7 of cycle 1 [23]).
2.6. Statistical analyses
Data analyses were descriptive; 2-sided 95% confidence
intervals (CIs) were calculated per treatment group and cycle
for the primary and secondary bleeding endpoints versus the
E2V/DNG reference group. The analyses were performed for
both the intent-to-treat (ITT) and the per-protocol (PP)
populations for cycles 2, 3 and 6. A t test was performed to
determine whether there are significant differences in the
mean number of unscheduled bleeding/spotting days
between E4 treatment groups and the E2V/DNG group.
The ITT population comprised all-subjects-treated (AST)
with at least one evaluable cycle, and PP population
comprised all ITT subjects without any major protocol
violation. Since the aim of the present study was to select an
E4/progestin combination for phase III development, the
present paper focussed on the outcome of primary and
secondary bleeding parameters in the PP population. The
safety analysis was performed for the AST population, and
only tabulations and frequencies are presented.
Since this was an exploratory study, the sample size was
based on the precision of the estimates in the treatment
groups. When the frequencies of absence of withdrawal
bleeding and of unscheduled intracyclic bleeding are
15–20% in a group, a size of 80 evaluable subjects per
group leads to standard errors of 4–4.5%.3. Results
3.1. Study population
A total of 396 women were randomised (Fig. 1), of whom
389 (98.2%) received study medication, and 316 completed
the study (79.8%). The number of completers was highest for15E4/DRSP (72/79; 91.1%) and E2V/DNG (70/78; 89.7%) and
was lowest for 20E4/LNG (54/77; 70.1%) (Fig. 1). TE-AEs
were the most common reason for discontinuing the study (41/
80; 51.3%). Seven women who had been randomised withdrew
from the study before receiving treatment.
The proportion of switchers (66.8% overall) and starters
(33.2% overall) was generally similar across treatment
groups (Table 1). Of the 41 women who discontinued due
to AEs, 27 (65.9%) were switchers and 14 (34.1%) were
starters. The completion rate was similar among starters, but
among switchers, it was highest for E2V/DNG and 15E4/
DRSP (97.4% and 96.2%, respectively) (data not shown).
Demographic and baseline characteristics were similar
across the treatment groups, with the exception of the
proportion of smokers, which varied between 10.7% for
20E4/DRSP and 24.7% for 20E4/LNG (Table 1).
3.2. Primary bleeding parameters
The frequency of unscheduled bleeding/spotting was lower
in the E4/DRSP groups across treatment cycles 2, 3 and 6,
compared to the other treatment groups. By cycle 6, the
frequency varied between 33.8% in the 15E4/DRSP group and
47.8% in the E2V/DNG group (Table 2 and Fig. 2). The
maximum intensity of unscheduled bleeding (≥2 sanitary
protections needed) per cycle increased over time in the E2V/
DNG group (up to 60%) and stayed the same with minor
fluctuations in the 15 mg E4/LNG and 15 mg E4/DRSP groups
(25–35%) (data not shown).
For both switchers and starters, the incidence of unscheduled
bleeding/spotting generally decreased with time in all groups.
By cycle 6, the frequency of unscheduled bleeding/spotting
varied in switchers between 29.3% for 15E4/DRSP and 48.7%
for 20E4/DRSP, and in starters, it varied between 38.5% for
20E4/LNG and 66.7% for E2V/DNG (Fig. 2).
The frequency of women with absence of withdrawal
bleeding was b20% for all E4 treatment groups throughout the
study. For E4/DRSP, it was absent for 1.3–1.5% in cycle 2,
1.5–2.8% in cycle 3 and 3.5–3.8% in cycle 6. In the E4/LNG
groups, these frequencies were 2.9–9.9%, 10.8–13.6% and
14.0–18.5%, respectively, and for E2V/DNG, these were
12.1%, 16.4% and 27.1%, respectively. By cycle 6, this resulted
in a difference of 23.6% fewer subjects with an absence of
withdrawal bleeding in the 15E4/DRSP group than in the E2V/
DNG group (95% CI: −35.9, −11.3) (Table 2 and Fig. 3).
In starters, none or only one single subject in any treatment
group had an absence of withdrawal bleeding in cycle 2 or 3. By
cycle 6, this remained the same in the E4 treatment groups but
increased to 22.2% for E2V/DNG. For switchers, the pattern
was similar to the overall population, showing that the lowest
incidence of absence of withdrawal bleeding was observed in
the E4/DRSP groups in any cycle (data not shown).
3.3. Secondary bleeding parameters
Throughout the study, the frequency of unscheduled
intracyclic bleeding was highest for E2V/DNG (35.8–45.5%)
Fig. 1. Subject disposition by treatment group (all-subjects-randomised population). Subject disposition in a study evaluating the bleeding pattern and cycle
control of four contraceptive combinations containing E4 (15 and 20 mg E4 combined with either 3 mg DRSP or 150 mcg LNG) and a marketed quadriphasic
combination containing E2V/DNG. The E4 combinations were administrated in a 24/4-day regimen while the E2V/DNG combination was administered in a 26/
2-day regimen. More women receiving the 15 mg E4/DRSP combination or the E2V/DNG combination completed the study in comparison to the other groups.
DNG: dienogest; DRSP: drospirenone; E4: estetrol; E2V: estradiol valerate; LNG: levonorgestrel.
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reported frequency of unscheduled bleeding was b20% for 20E4/
LNG (18.9%) and 15E4/DRSP (16.9%) (Table 2 and Fig. 3).
Unscheduled bleeding/spotting on individual days during
cycle 1 was reported by 12–34% of women in the E4/DRSP
groups and by 16–46%ofwomen in the other groups. The daily
frequency of unscheduled bleeding/spotting decreased notably
by cycle 2 and remained lower in subsequent cycles in all
groups. By cycle 6, the occurrence of unscheduled bleeding/
spotting on any cycle day was 3–8% for 15E4/DRSP, 9–19%
for the other E4 groups and 10–27% for E2V/DNG (Fig. 4). As
shown in Fig. 5, the mean number of days with unscheduled
bleeding/spotting was statistically significantly lower in the 15
mg E4/DRSP group in comparison to the E2V/DNG group at
cycles 2, 3 and 6 (at cycle 1, there was no statistical difference
between the five groups — data not shown). By cycle 6, the
mean number of days with unscheduled bleeding/spotting
varied between 1.3 in the 15E4/DRSP group and 2.9 in the E2V/
DNG group (p=.008) (Fig. 5).
Earlywithdrawal bleeding (between cycle days 21 and 24)was
variable across the cycles. The incidence decreased or remainedTable 1
Main demographics and baseline characteristics (AST population)
15E4/DRSP
N=79
20E4/DRSP
N=75
1
N
Mean age, years (SD) 24.3 (4.6) 24.0 (4.5) 2
Mean BMI, kg/m2 (SD) 22.9 (3.0) 23.1 (2.8) 2
Current smoking, n (%) 18 (22.8) 8 (10.7) 1
Switchers, n (%) 51 (64.6) 50 (66.7) 5
Starters, n (%) 28 (35.4) 25 (33.3) 3
BMI: body mass index; DNG: dienogest; DRSP: drospirenone; E4: estetrol; E2V
N: number of subjects in the AST population; SD: standard deviation.stable over time and, by cycle 6, it was lowest for 15E4/DRSP
(20.0%) and 20E4/LNG (17.0%). The incidence in the E2V/DNG
reference group was 23.9% by cycle 6 (data not shown).
3.4. Safety parameters and vital signs
The frequency of TE-AEs was 64.6% for 15E4/DRSP and
varied between 71.8% and 80.0% in the other groups (Table 3).
Themajority ofwomen hadmild ormoderate TE-AEs. Between
23.1% and 45.5% of women reported a drug-related TE-AE in
the various groups. The incidence of headache/migraine was
2.5–9.3%, and of anxiety/depression, it was 0%–6.5% across
groups. One SAE was reported: thyroid neoplasm in the E2V/
DNG group, considered by the investigator as not related to
study treatment. No apparent dose- or drug-related trends were
observed in standard safety laboratory parameters. There were
no in-treatment pregnancies, and ovulation was inhibited for all
treatments during the first four cycles tested.
Mean changes from baseline in systolic and diastolic blood
pressure and heart rate were generally small throughout the
study in all groups, without any obvious trends.5E4/LNG
=80
20E4/LNG
N=77
E2V/DNG
N=78
Overall
N=389
4.8 (4.8) 24.0 (3.6) 23.4 (3.5) 24.1 (4.2)
2.6 (3.0) 22.6 (2.8) 22.4 (2.8) 22.7 (2.9)
8 (22.5) 19 (24.7) 10 (12.8) 73 (18.8)
0 (62.5) 55 (71.4) 54 (69.2) 260 (66.8)
0 (37.5) 22 (28.6) 24 (30.8) 129 (33.2)
: estradiol valerate; LNG: levonorgestrel; n: number of subjects with data;
Table 2
Primary and secondary bleeding outcome parameters (PP population)
15E4/DRSP
N=77
20E4/DRSP
N=73
15E4/LNG
N=77
20E4/LNG
N=76
E2V/DNG
N=75
Occurrence of unscheduled bleeding and/or spotting
Treatment cycle 2
• Bleeding/spotting, n/N (%) 34/75 (45.3) 28/68 (41.2) 43/71 (60.6) 38/68 (55.9) 40/66 (60.6)
• Difference from E2V/DNG, rate (95% CI) −15.3 (−31.6, 1.0) −19.4 (−36.0, −2.8) 0.0 (−16.4, 16.3) −4.7 (−21.4, 12.0)
• Treatment cycle 3
• Bleeding/spotting, n/N (%) 39/72 (54.2) 29/67 (43.3) 35/65 (53.8) 39/66 (59.1) 39/68 (57.4)
• Difference from E2V/DNG, rate (95% CI) −3.2 (−19.6, 13.3) −14.1 (−30.8, 2.6) −3.5 (−20.4, 13.4) 1.7 (−15.0, 18.4)
Treatment cycle 6
• Bleeding/spotting, n/N (%) 22/65 (33.8) 29/57 (50.9) 28/58 (48.3) 22/53 (41.5) 32/67 (47.8)
• Difference from E2V/DNG, rate (95% CI) −13.9 (−30.5, 2.7) 3.1 (−14.5, 20.8) 0.5 (−17.0, 18.1) −6.2 (−24.1, 11.6)
Occurrence of unscheduled bleeding
Treatment cycle 2
• Bleeding, n/N (%) 20/75 (26.7) 16/68 (23.5) 29/71 (40.8) 20/68 (29.4) 30/66 (45.5)
• Difference from E2V/DNG, rate (95% CI) −18.8 (−34.4, −3.2) −21.9
(−37.6, −6.2)
−4.6
(−21.2, 12.0)
−16.0
(−32.2, 0.1)
• Treatment cycle 3
• Bleeding, n/N (%) 22/72 (30.6) 15/67 (22.4) 24/65 (36.9) 22/66 (33.3) 29/68 (42.6)
• Difference from E2V/DNG, rate (95% CI) −12.1 (−28.0, 3.8) −20.6 (−35.7, −4.8) −5.7 (−22.3, 10.9) −9.3 (−25.7, 7.0)
Treatment cycle 6
• Bleeding, n/N (%) 11/65 (16.9) 13/57 (22.8) 21/58 (36.2) 10/53 (18.9) 24/67 (35.8)
• Difference from E2V/DNG, rate (95% CI) −18.9 (−33.6, −4.2) −13.1 (−28.8, 2.8) 0.4 (−16.5, 17.3) −17.0 (−32.5, −1.4)
Absence of withdrawal bleeding
Treatment cycle 2
• No withdrawal, n/N (%) 1/75 (1.3) 1/68 (1.5) 7/71 (9.9) 2/68 (2.9) 8/66 (12.1)
• Difference from E2V/DNG, rate (95% CI) −10.8 (−19.1, −2.5) −10.6 (−19.0, −2.3) −2.3 (−12.8, 8.2) −9.2 (−18.0, −0.3)
Treatment cycle 3
• No withdrawal,. n/N (%) 2/72 (2.8) 1/67 (1.5) 7/65 (10.8) 9/66 (13.6) 11/67 (16.4)
• Difference from E2V/DNG, rate (95% CI) −13.6 (−23.3, −4.0) −14.9 (−24.3, −5.6) −5.6 (−17.3, 6.0) −2.8 (−14.9, 9.4)
Treatment cycle 6
• No withdrawal, n/N (%) 2/57 (3.5) 2/53 (3.8) 10/54 (18.5) 7/50 (14.0) 16/59 (27.1)
• Difference from E2V/DNG, rate (95% CI) −23.6 (−35.9, −11.3) −23.4 (−35.8, −10.9) −8.6 (−24.0, 6.8) −3.1 (−28.0, 1.8)
CI: confidence interval; DNG: dienogest; DRSP: drospirenone; E4: estetrol; E2V: estradiol valerate; LNG: levonorgestrel; n: number of subjects with data;
N: number of subjects in the PP population.
Fig. 2. Frequency (%) of women with unscheduled bleeding/spotting in
cycle 6. Percentage of women with unscheduled bleeding/spotting in each
treatment group in cycle 6. The data are presented overall and in the subsets
of switchers and starters (PP population). DNG: dienogest; DRSP:
drospirenone; E4: estetrol; E2V: estradiol valerate; LNG: levonorgestrel.
Fig. 3. Frequency (%) ofwomenwith absence ofwithdrawal bleeding/spotting in
cycle 6. Percentage of subjects with absence of withdrawal bleeding and
unscheduled bleeding in each treatment group in cycle 6 (PP population).
Absence of withdrawal bleeding ≤20%, and/or ≤20% unscheduled intracyclic
bleeding after six treatment cycles, was set as a limit (dotted bar). DNG:
dienogest; DRSP: drospirenone; E4: estetrol; E2V: estradiol valerate; LNG:
levonorgestrel.
370 D. Apter et al. / Contraception 94 (2016) 366–373
Fig. 4. Incidence of scheduled and unscheduled bleeding/spotting on a daily basis during the six treatment cycles (PP population). Bleeding or spotting reported
during cycle days 5–24 was considered unscheduled. Early withdrawal bleeding/spotting occurs between cycle days 21 and 24. DNG: dienogest; DRSP:
drospirenone; E4: estetrol; E2V: estradiol valerate; LNG: levonorgestrel.
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Firstly, there were no safety concerns for any of the
treatments in this study.
The aim of the present study was to select the E4/
progestin dosing regimen for phase III development, based
on an optimal bleeding pattern and cycle control. For this
reason, absence of withdrawal bleeding for at most 20% of
the women and unscheduled intracyclic bleeding without
spotting for at most 20% of the women were set as limits.
After six cycles, the 15 mg E4/DRSP and the 20 mg E4/LNG
combinations were the only ones meeting both criteria:
absence of withdrawal bleeding was observed for 3.5% and
14.0%, respectively, and unscheduled intracyclic bleeding
was observed for 16.9% and 18.9%, respectively.Fig. 5. Mean number of unscheduled bleeding/spotting days in cycles 2, 3
and 6. Bleeding or spotting reported during cycle days 5–24 was considered
unscheduled. The mean number of unscheduled bleeding (black bars)/
spotting (white bars) days was calculated for each treatment group in the PP
population. t Test showed a significant difference at cycles 2, 3 and 6
between 15E4/DRSP and E2V/DNG treatment groups (*pb .05, **pb .005).
DNG: dienogest; DRSP: drospirenone; E4: estetrol; E2V: estradiol valerate;
LNG: levonorgestrel.Regular monthly withdrawal bleeding is desirable as it
reassures the user that she is not pregnant [24]. Therefore, the
3.5% absence of withdrawal bleeding in the 15E4/DRSP
group is considered a very positive feature. By cycle 6, the
lowest frequency of unscheduled bleeding and spotting was
also observed in the 15E4/DRSP group (33.8%), which was
considerably lower than the 47.8% observed in the E2V/
DNG reference group. Only 8.9% of subjects in the 15E4/
DRSP group discontinued prematurely (compared with a
discontinuation rate of between 10.3% and 29.9% in the
other groups), which may be related to the favourable cycle
control with this treatment regimen.
Since E4 is a natural oestrogen, Qlaira® was chosen as
reference COC in the present study because it also contains a
natural oestrogen (E2V). It is noteworthy that the incidence of
unscheduled bleeding in the E2V/DNG group (35.8%) is in
contrast with the 14% reported by Ahrendt et al. [9]. An
explanation may be the different definitions used for the term
‘unscheduled’: days 5–24 in the present study and days 3–21 in
the E2V/DNG study [9]. This is also supported by the fact that,
during E2V/DNG treatment, substantial bleeding was reported
between days 21 and 24 (Fig. 4). A satisfactory cycle control has
been described for combinations of DRSP or LNGwith 20 mcg
EE as the oestrogen [25,26]. The results observed with 15 mg
E4/DRSP are in line with these findings.
In conclusion, the 15 mg E4/DRSP combination has been
shown to be the most efficacious in terms of bleeding pattern
and cycle control, compared with the other combinations
investigated. Therefore, this COC seems to be the preferred
combination for further phase III clinical development.Acknowledgements
The study was funded by Estetra SPRL (Liège, Belgium)
and by the Walloon Government (grant number: C6139).
Table 3
Incidence of TE-AEs, n (%) (AST population)
15E4/DRSP
N=79
20E4/DRSP
N=75
15E4/LNG
N=80
20E4/LNG
N=77
E2V/DNG
N=78
TE-AEs 51 (64.6) 60 (80.0) 60 (75.0) 57 (74.0) 56 (71.8)
Deaths 0 0 0 0 0
SAE 0 0 0 0 1 (1.3)
TE-AEs leading to withdrawal 5 (6.3) 8 (10.7) 10 (12.5) 12 (15.6) 4 (5.1)
TE-AEs of known severe intensity 3 (3.8) 2 (2.7) 1 (1.3) 2 (2.6) 3 (3.9)
Drug-related TE-AEs
• Overall 20 (25.3) 31 (41.3) 28 (35.0) 35 (45.5) 18 (23.1)
• Headache/migraine 3 (3.8) 7 (9.3) 2 (2.5) 6 (7.8) 5 (6.4)
• Anxiety/depression 0 0 1 (1.3) 5 (6.5) 1 (1.3)
AST: all-subjects treated; DNG: dienogest; DRSP: drospirenone; E4: estetrol; E2V: estradiol valerate; LNG: levonorgestrel; n: number of subjects with data;
N: number of subjects in the AST population; SAE: serious adverse event; TE-AEs: treatment-emergent adverse events.
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